TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 26 Week, Randomized, Double-blind, Parallel-group, Active Controlled, Multicenter, Multinational Safety Study Evaluating the Risk of Serious Asthma-related Events During Treatment With Symbicort®, a Fixed Combination of Inhaled Corticosteroid (ICS) (Budesonide) and a Long Acting β2-agonist (LABA) (Formoterol) as Compared to Treatment With ICS (Budesonide) Alone in Adult and Adolescent (≥12 Years of Age) Patients With Asthma
Brief Summary: The purpose of the study is to evaluate the safety of Symbicort compared to inhaled corticosteroid alone during 6 months in adult and adolescent patients with asthma


Options:
A: Intervention Type: DRUG; Name: FLUTIFORM® (Formoterol fumarate / Fluticasone propionate); Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Symbicort pMDI | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonide pMDI | Intervention Type: DRUG; Name: Symbicort pMDI; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: budesonide pMDI; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: beclomethasone dipropionate plus formoterol fumarate combination; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone propionate plus salmeterol xinafoate combination; Assigned to Arm(s): N/A
D: Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) MDI | Arm Label: F/SC DPI 250/50 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/salmeterol (F/SC) DPI | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) MDI; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Fluticasone propionate/salmeterol (F/SC) DPI; Assigned to Arm(s): F/SC DPI 250/50 mcg BID

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 26 Week, Randomized, Double-blind, Parallel-group, Active Controlled, Multicenter, Multinational Safety Study Evaluating the Risk of Serious Asthma-related Events During Treatment With Symbicort®, a Fixed Combination of Inhaled Corticosteroid (ICS) (Budesonide) and a Long Acting β2-agonist (LABA) (Formoterol) as Compared to Treatment With ICS (Budesonide) Alone in Adult and Adolescent (≥12 Years of Age) Patients With Asthma
Brief Summary: The purpose of the study is to evaluate the safety of Symbicort compared to inhaled corticosteroid alone during 6 months in adult and adolescent patients with asthma


Options:
A: Arm Label: Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Vilanterol, Drug: Placebo Inhalation Powder Diskus | Arm Label: Salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol Inhalation Powder, Drug: Placebo Inhalation Powder NDPI | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Inhalation Powder NDPI, Drug: Placebo Inhalation Powder Diskus | Intervention Type: DRUG; Name: Vilanterol; Assigned to Arm(s): Vilanterol | Intervention Type: DRUG; Name: Salmeterol Inhalation Powder; Assigned to Arm(s): Salmeterol | Intervention Type: DRUG; Name: Placebo Inhalation Powder NDPI; Assigned to Arm(s): Placebo, Salmeterol | Intervention Type: DRUG; Name: Placebo Inhalation Powder Diskus; Assigned to Arm(s): Placebo, Vilanterol
B: Intervention Type: DRUG; Name: beclomethasone dipropionate plus formoterol fumarate combination; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone propionate plus salmeterol xinafoate combination; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Symbicort pMDI | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonide pMDI | Intervention Type: DRUG; Name: Symbicort pMDI; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: budesonide pMDI; Assigned to Arm(s): 2
D: Arm Label: Fluticasone furoate/Vilanterol (GW642444); Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate/Vilanterol Inhalation Powder, Drug: Placebo (2) | Arm Label: Fluticasone propionate/salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/salmeterol Inhalation Powder, Drug: Placebo (1) | Intervention Type: DRUG; Name: Fluticasone furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444) | Intervention Type: DRUG; Name: Fluticasone propionate/salmeterol Inhalation Powder; Assigned to Arm(s): Fluticasone propionate/salmeterol | Intervention Type: DRUG; Name: Placebo (1); Assigned to Arm(s): Fluticasone propionate/salmeterol | Intervention Type: DRUG; Name: Placebo (2); Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 26 Week, Randomized, Double-blind, Parallel-group, Active Controlled, Multicenter, Multinational Safety Study Evaluating the Risk of Serious Asthma-related Events During Treatment With Symbicort®, a Fixed Combination of Inhaled Corticosteroid (ICS) (Budesonide) and a Long Acting β2-agonist (LABA) (Formoterol) as Compared to Treatment With ICS (Budesonide) Alone in Adult and Adolescent (≥12 Years of Age) Patients With Asthma
Brief Summary: The purpose of the study is to evaluate the safety of Symbicort compared to inhaled corticosteroid alone during 6 months in adult and adolescent patients with asthma


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Symbicort pMDI | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonide pMDI | Intervention Type: DRUG; Name: Symbicort pMDI; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: budesonide pMDI; Assigned to Arm(s): 2
B: Arm Label: Fluticasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Arm Label: Montelukast; Type: EXPERIMENTAL; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Arm Label: Fluticasone plus salmeterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Intervention Type: DRUG; Name: fluticasone; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast | Intervention Type: DRUG; Name: Fluticasone plus salmeterol; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast
C: Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Salmeterol xinafoate; Assigned to Arm(s): N/A
D: Arm Label: tiotropium low dose; Type: EXPERIMENTAL; Interventions: Drug: placebo, Drug: tiotropium Respimat® low dose | Arm Label: tiotropium high dose; Type: EXPERIMENTAL; Interventions: Drug: tiotropium Respimat® high dose, Drug: placebo | Arm Label: 50 mcg salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo, Drug: 50 mcg salmeterol HFA MDI | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): tiotropium low dose | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: tiotropium Respimat® low dose; Assigned to Arm(s): tiotropium low dose | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 50 mcg salmeterol | Intervention Type: DRUG; Name: tiotropium Respimat® high dose; Assigned to Arm(s): tiotropium high dose | Intervention Type: DRUG; Name: 50 mcg salmeterol HFA MDI; Assigned to Arm(s): 50 mcg salmeterol | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): tiotropium high dose

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Oral Azithromycin (500 Mg OD) as a Supplement to Standard Care for Adult Patients With Acute Exacerbations of Asthma
Brief Summary: Acute attacks (exacerbations) of asthma are common and cause a great deal of suffering in asthmatic patients. Current treatments for asthma attacks are not completely effective and new and better treatments are needed. Viruses often cause asthma attacks and bacterial lung infections have also been associated with asthma attacks. However, the role for bacteria is uncertain. Current asthma guidelines for doctors treating asthma exacerbations do not recommend the routine use of antibiotics. The investigators would like to investigate whether or not azithromycin, which is a safe and well tolerated antibiotic (an antibacterial) that has been used for many years in the treatment of respiratory disease, might be of benefit in asthma attacks. As there is some evidence that azithromycin has anti-viral properties this may add to its benefits (antibiotics don't usually affect viruses). By looking at the effect of azithromycin on asthma attacks this will help us to show whether or not azithromycin should be recommended during an acute asthma attack in addition to the usual care that is provided to these patients as it may help them recover quicker from the exacerbation. The investigators will also be able to look at why azithromycin may be effective - if it is having an anti-bacterial and/or anti-viral effect.


Options:
A: Arm Label: Antibiotics; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo mixture | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Antibiotics | Intervention Type: OTHER; Name: Placebo mixture; Assigned to Arm(s): Placebo
B: Arm Label: Azithromycin (Zithromax); Type: EXPERIMENTAL; Interventions: Drug: Zithromax | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zithromax; Assigned to Arm(s): Azithromycin (Zithromax) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Telithromycin; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Oral Azithromycin (500 Mg OD) as a Supplement to Standard Care for Adult Patients With Acute Exacerbations of Asthma
Brief Summary: Acute attacks (exacerbations) of asthma are common and cause a great deal of suffering in asthmatic patients. Current treatments for asthma attacks are not completely effective and new and better treatments are needed. Viruses often cause asthma attacks and bacterial lung infections have also been associated with asthma attacks. However, the role for bacteria is uncertain. Current asthma guidelines for doctors treating asthma exacerbations do not recommend the routine use of antibiotics. The investigators would like to investigate whether or not azithromycin, which is a safe and well tolerated antibiotic (an antibacterial) that has been used for many years in the treatment of respiratory disease, might be of benefit in asthma attacks. As there is some evidence that azithromycin has anti-viral properties this may add to its benefits (antibiotics don't usually affect viruses). By looking at the effect of azithromycin on asthma attacks this will help us to show whether or not azithromycin should be recommended during an acute asthma attack in addition to the usual care that is provided to these patients as it may help them recover quicker from the exacerbation. The investigators will also be able to look at why azithromycin may be effective - if it is having an anti-bacterial and/or anti-viral effect.


Options:
A: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Azithromycin, 250 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Macrolide Antibiotic (Azithromycin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Macrolide Antibiotic (Azithromycin); Assigned to Arm(s): Azithromycin, 250 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin 250 mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin 250 mg; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: Azithromycin (Zithromax); Type: EXPERIMENTAL; Interventions: Drug: Zithromax | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zithromax; Assigned to Arm(s): Azithromycin (Zithromax) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Psychodynamic Motivation and Training Program (PMT) as Secondary Prevention in Patients With Stable Coronary Heart Disease
Brief Summary: The purpose of this study is to examine the effectiveness of a Psychodynamic Motivation and Training Program (PMT) for the improvement of physical fitness in patients with stable coronary heart disease as compared to advice in exercise training or treatment as usual.


Options:
A: Arm Label: Psychodynamic Motivation and Training Program (PMT); Type: EXPERIMENTAL; Interventions: Behavioral: Psychodynamic Motivation and Training Program (PMT) | Arm Label: Advice in Exercise Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Advice in Exercise Training (+Ex) | Arm Label: Treatment as usual (TAU); Type: OTHER; Interventions: Other: Treatment as usual (TAU) | Intervention Type: BEHAVIORAL; Name: Psychodynamic Motivation and Training Program (PMT); Assigned to Arm(s): Psychodynamic Motivation and Training Program (PMT) | Intervention Type: BEHAVIORAL; Name: Advice in Exercise Training (+Ex); Assigned to Arm(s): Advice in Exercise Training | Intervention Type: OTHER; Name: Treatment as usual (TAU); Assigned to Arm(s): Treatment as usual (TAU)
B: Arm Label: Cardio fit; Type: EXPERIMENTAL; Interventions: Behavioral: CardioFit | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CardioFit; Assigned to Arm(s): Cardio fit
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stepping Up to Health | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Stepping Up to Health | Intervention Type: BEHAVIORAL; Name: Stepping Up to Health; Assigned to Arm(s): 1, 2
D: Intervention Type: BEHAVIORAL; Name: multifactorial continued educational - behavioural programme; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Alcohol Exposed Pregnancy Risk
Brief Summary: The EARLY Randomized Controlled Trial (RCT) will test the finalized EARLY preventive intervention against one comparison and one control condition. Because prevention of Alcohol-exposed pregnancy (AEP) will be achieved whether woman change drinking OR contraception, the primary endpoints will be rates of risky drinking and ineffective contraception at six-month follow-up, in addition to dichotomously defined "successful outcome" that will be observed whenever a woman has sufficiently altered one or both of the behaviors that placed her at risk of Alcohol-Exposed Pregnancy (AEP). The goal is to identify a transferable intervention that effectively reduces behaviors that put women at risk for AEP and alcohol-related birth defects including FASD.


Options:
A: Arm Label: Standard Positive Prevention Counselling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational intervention counselling plus SPP | Arm Label: Alcohol Motivational intervention counselling plus SPP; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational intervention counselling plus SPP | Intervention Type: BEHAVIORAL; Name: Motivational intervention counselling plus SPP; Assigned to Arm(s): Alcohol Motivational intervention counselling plus SPP, Standard Positive Prevention Counselling
B: Arm Label: EARLY; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing plus feedback | Arm Label: Video Information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Video | Arm Label: Informational Brochure; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Informational Brochure | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing plus feedback; Assigned to Arm(s): EARLY | Intervention Type: BEHAVIORAL; Name: Video; Assigned to Arm(s): Video Information | Intervention Type: BEHAVIORAL; Name: Informational Brochure; Assigned to Arm(s): Informational Brochure
C: Arm Label: C; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: MI; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): MI
D: Arm Label: Standard Brief Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Standard Brief Intervention | Arm Label: Enhanced Brief Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Brief Intervention | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control: Information and Feedback | Intervention Type: BEHAVIORAL; Name: Standard Brief Intervention; Assigned to Arm(s): Standard Brief Intervention | Intervention Type: BEHAVIORAL; Name: Enhanced Brief Intervention; Assigned to Arm(s): Enhanced Brief Intervention | Intervention Type: BEHAVIORAL; Name: Control: Information and Feedback; Assigned to Arm(s): Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Alcohol Exposed Pregnancy Risk
Brief Summary: The EARLY Randomized Controlled Trial (RCT) will test the finalized EARLY preventive intervention against one comparison and one control condition. Because prevention of Alcohol-exposed pregnancy (AEP) will be achieved whether woman change drinking OR contraception, the primary endpoints will be rates of risky drinking and ineffective contraception at six-month follow-up, in addition to dichotomously defined "successful outcome" that will be observed whenever a woman has sufficiently altered one or both of the behaviors that placed her at risk of Alcohol-Exposed Pregnancy (AEP). The goal is to identify a transferable intervention that effectively reduces behaviors that put women at risk for AEP and alcohol-related birth defects including FASD.


Options:
A: Arm Label: EARLY; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing plus feedback | Arm Label: Video Information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Video | Arm Label: Informational Brochure; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Informational Brochure | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing plus feedback; Assigned to Arm(s): EARLY | Intervention Type: BEHAVIORAL; Name: Video; Assigned to Arm(s): Video Information | Intervention Type: BEHAVIORAL; Name: Informational Brochure; Assigned to Arm(s): Informational Brochure
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Brief intervention | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Control group | Intervention Type: OTHER; Name: Brief intervention; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): 2
C: Arm Label: Brief Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Enhancement Therapy | Arm Label: Assessed Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: No Contact Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement Therapy; Assigned to Arm(s): Brief Intervention Group
D: Arm Label: Screened Only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Screened and Assessed; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Motivational Intervention | Intervention Type: BEHAVIORAL; Name: Brief Motivational Intervention; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Alcohol Exposed Pregnancy Risk
Brief Summary: The EARLY Randomized Controlled Trial (RCT) will test the finalized EARLY preventive intervention against one comparison and one control condition. Because prevention of Alcohol-exposed pregnancy (AEP) will be achieved whether woman change drinking OR contraception, the primary endpoints will be rates of risky drinking and ineffective contraception at six-month follow-up, in addition to dichotomously defined "successful outcome" that will be observed whenever a woman has sufficiently altered one or both of the behaviors that placed her at risk of Alcohol-Exposed Pregnancy (AEP). The goal is to identify a transferable intervention that effectively reduces behaviors that put women at risk for AEP and alcohol-related birth defects including FASD.


Options:
A: Arm Label: Control Condition; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: CHARM Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: CHARM | Intervention Type: BEHAVIORAL; Name: CHARM; Assigned to Arm(s): CHARM Intervention
B: Arm Label: 1 Standard Care (SC); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2 Standard Care + Educational (SCE); Type: OTHER; Interventions: Behavioral: educational instruction in clinic | Arm Label: 3 Standard Care + Educational + Phone Calls (SCEP); Type: OTHER; Interventions: Behavioral: educational instruction and phone follow-up | Intervention Type: BEHAVIORAL; Name: educational instruction and phone follow-up; Assigned to Arm(s): 3 Standard Care + Educational + Phone Calls (SCEP) | Intervention Type: BEHAVIORAL; Name: educational instruction in clinic; Assigned to Arm(s): 2 Standard Care + Educational (SCE)
C: Arm Label: EARLY; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing plus feedback | Arm Label: Video Information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Video | Arm Label: Informational Brochure; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Informational Brochure | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing plus feedback; Assigned to Arm(s): EARLY | Intervention Type: BEHAVIORAL; Name: Video; Assigned to Arm(s): Video Information | Intervention Type: BEHAVIORAL; Name: Informational Brochure; Assigned to Arm(s): Informational Brochure
D: Arm Label: SAFE Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SAFE Behavioral Intervention | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: BEHAVIORAL; Name: SAFE Behavioral Intervention; Assigned to Arm(s): SAFE Intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: C